Recent

% | $
Quotes you view appear here for quick access.

Acorda Therapeutics, Inc. (ACOR) Message Board

  • fastmoneypete fastmoneypete Oct 8, 2012 11:16 AM Flag

    Group Health negative AMPYRA review updated on October 4, 6:53pm

    Looks like another Questcor in the making.
    Group Health updates coverage and withdraws Ampyra for MS, which was revised on Thursday, October 4 at 6:53pm and published today on their website - so this is a new update! Search Ampyra and you can download the pdf. Then go to Properties of the downloaded file to verify the revision date (October 4) for this data.:

    Drug Name: Dalfampridine (Ampyra) Dosage, Route: Tablet, oral
    Drug Class/Indication: Multiple sclerosis
    Decision: Add criteria.
    GH Closed Formulary GH Open Formulary Medicare Part D
    Formulary Status Non-formulary with
    criteria
    Tier 3 with criteria Tier 4 (non-preferred)
    Drug Criteria:
    Medical necessity review required.
    Rationale:
    Dalfampridine provides outcomes of questionable clinical significance and lacks long-term safety data

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACOR
34.61+0.49(+1.44%)Jul 28 4:00 PMEDT